Protein Kinase C- β ( PKC- β ) Inhibition: A Promise not yet Fulfilled Ruboxistaurin, an oral PKC- β, was withdrawn on March 15, 2007 by Eli Lilly
Dual Inhibition of Classical Protein Kinase C- α and Protein Kinase C- β Isoforms Protects Against Diabetic Nephropathy Diabetes 2013;62:1010-1011
ASCEND Trial: Endothelin Receptor Antagonist Avosentan Significantly Decreased Albuminuria Terminated due to increased CHF and deaths J Am Soc Nephrol 2010;21:527–535
Addition of Atrasentan, an Endothelin Receptor Antagonist, to RAS Blockade Reduces Albuminuria in Diabetic Nephropathy Baseline UACR ~400 mg/g CR J Am Soc Nephrol 2011;22:763-772
Atrasentan Restores Endothelial Glycocalyx Thickness Diabetes 2016;65:2429-2439
Pirfenidone, an Inhibitor of TGF- β at 1200 mg/d, but NOT 2400 mg/d, Improves eGFR from Baseline Pirfenidone (Esbriet) approved to treat idiopathic pulmonary fibrosis J Am Soc Nephrol 2011;22:1144–1151
Pentoxifylline-Lower Decline in eGFR and Greater UAE Reduction Baseline UAE ~1000 mg/day J Am Soc Nephrol 2015;26:220–229
CCX140-B (CCR2 Antagonist) Lowers Albuminuria in Patients with Type 2 DM Monocyte chemoattractant protein-1 (MCP-1), also called C-C chemokine receptor 2 (CCR2) Baseline UAE 400 mg/day Lancet Diabetes & Endo 2015;3:687-696
Pyridoxamine (Pyridorin), a Derivative of Vitamin B6, Inhibits the Formation of Advanced Glycation Endproducts I.V. form of Pyridorin for use in hospital-acquired acute kidney injury Nephron 2015;129:22–28
Finerenone, a 3 rd Generation Nonsteroidal Mineralocorticoid Receptor Antagonists Lowers Albuminuria Baseline UACR ~200 mg/g CR JAMA 2015;314:884-894
Patiromer (Veltassa)— Twice Daily Lowered Potassium Levels FDA Approved on October 22, 2015 but with a Black Box Warning N Engl J Med 2015;372:211-221
Sodium Zirconium Cyclosilicate (ZS-9) 3X Daily X2 days ↓ Hyperkalemia AstraZeneca receives Complete Response Letter from FDA May 27, 2016 JAMA 2014;312:2223-2233
Metformin Improves Whole-Body Glycocalyx Barrier Properties Cardiovasc Diabetol 2013;12:175
Recommend Documents
Inhibition of Fyn Kinase for Disease- Modifying Therapy of Alzheimers Disease
Abietane Diterpenoids from Plectranthus spp. as a potential new class of
New Insights into Covalent Enzyme Inhibition Application to Anti-Cancer Drug
Progress on the co-crystallization of Thermoplasma acidophilum nucleoside
Click chemistry for advanced drug discovery applications of human protein
Prediction of Human Protein Kinase Substrate Specificities Javad Safaei 1 ,
Pierce College Promise PIERCE PROMISE PIERCE PROMISE PIERCE PROMISE
Elucidating cell-to-cell variability in phosphorylation of the ERK MAP kinase
1 Excitatory Inhibitory excitation inhibition 2 excitation excitation
Protein Kinase C Modulates Wnt Signaling In Colon Tumoral Cell Lines Dra
BLU-5937: A Highly Selective P2X3 Homotrimeric Receptor Antagonist, Exhibits
A small molecule glycomime.c antagonist of E-selec.n and CXCR4
CCR5 Antagonist CCR5 Antagonist Drug Development Issues Drug Development
Criteria for Evaluating a Group Literary Presentation SCC Department of English
The Presentation Secrets of Steve Jobs Carmine Gallo Columnist,
Naloxone in High Schools Purpose of this Presentation Educate High School
Affimer fimer Biother therapeut apeutics: ics: Th The precl eclinical
The Presentation Genius of Steve Jobs Table of Contents Steve Jobs
5/4/2016 Disclosure Information PT2385: HIF 2 Antagonist for the Treatment
DISCLOSURE No disclosures, financial, or otherwise to declare ANATOMY
The Glucagon Receptor Antagonist LGD-6972 Reduces Fasting and Postprandial
Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation